- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Accepts Filing for Investigational Narcolepsy Medication
The FDA has accepted for filing with priority review Jazz Pharmaceuticals’ new drug application for JZP-258. The investigational medicine targets cataplexy and excessive daytime sleepiness associated with narcolepsy.
The FDA has accepted for filing with priority review Jazz Pharmaceuticals’ new drug application for JZP-258. The investigational medicine targets cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy.
JZP-258 can be used in patients aged 7 or older who suffer from narcolepsy. The investigational medicine “is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or approximately 1000 to 1500 mg, less sodium than Xyrem (sodium oxybate),” according to a press release announcing the FDA's decision. Calcium, magnesium, and potassium cations are included in JZP-258.
The goal date for an FDA decision on JZP-258 is July 21, 2020. Currently, Xyrem is the only product approved to treat EDS and cataplexy in the same age group.
Cataplexy, a specific symptom of narcolepsy, is classified as the sudden, brief loss of muscle tone with retained consciousness that can be triggered by strong emotions like surprise or anger. Episodes of cataplexy commonly involve certain muscle groups, such as the arms and legs, head and neck, or the face and jaw.
“We developed JZP-258 to be a safer and long-term treatment option for patients. JZP-258 represents between 1000 and 1500 mg daily reduction of sodium for patients currently treated with Xyrem, depending on the dose,” said Robert Iannone, MD, executive vice president of research and development at Jazz Pharmaceuticals.
There is consensus in the scientific community that reducing daily sodium intake is associated with reductions in blood pressure and cardiovascular disease risk, explains Iannone. Individuals with narcolepsy have an increased risk of comorbidities including obesity, hypertension, and diabetes.
“We believe that JZP-258 has the potential to be an important treatment option for patients living with the life-long condition of narcolepsy,” he said.
The medicine can also be used to treat idiopathic hypersomnia in adult patients.
Although the exact mechanism of action of JZP-258 is not fully understood, researchers hypothesize the therapeutic effects of JZP-258 on sleep/wake symptoms are mediated through modulation of GABAB receptors as patients sleep.
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
Many sleep experts want to permanently stay in the standard time zone; Medicare will cover mental health counselors and marriage and family therapists beginning in January; a new Minnesota law requires hospitals to check if patients are eligible for financial assistance before referring medical debt for collections.
Read More
Meta-Analysis Reveals Varied Sleep Patterns in Intellectual Disabilities
October 24th 2023Individuals with genetic syndromes or neurodevelopmental conditions experienced shorter and poorer quality sleep, while those with heterogeneous intellectual disabilities had comparable duration but lower quality to controls.
Read More
